Correlation Between BriaCell Therapeutics and Dermata Therapeutics

Can any of the company-specific risk be diversified away by investing in both BriaCell Therapeutics and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining BriaCell Therapeutics and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between BriaCell Therapeutics Corp and Dermata Therapeutics Warrant, you can compare the effects of market volatilities on BriaCell Therapeutics and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in BriaCell Therapeutics with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of BriaCell Therapeutics and Dermata Therapeutics.

Diversification Opportunities for BriaCell Therapeutics and Dermata Therapeutics

0.03

Correlation Coefficient

BriaCell Therapeutics  Dermata Therapeutics

Significant diversification

The 3 months correlation between BriaCell and Dermata is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding BriaCell Therapeutics Corp and Dermata Therapeutics Warrant in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and BriaCell Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on BriaCell Therapeutics Corp are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of BriaCell Therapeutics i.e., BriaCell Therapeutics and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between BriaCell Therapeutics and Dermata Therapeutics

Assuming the 90 days horizon BriaCell Therapeutics Corp is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, BriaCell Therapeutics Corp is 23.11 times less risky than Dermata Therapeutics. The stock trades about -0.02 of its potential returns per unit of risk. The Dermata Therapeutics Warrant is currently generating about 0.23 of returns per unit of risk over similar time horizon. If you would invest  1.10  in Dermata Therapeutics Warrant on September 20, 2024 and sell it today you would earn a total of  0.35  from holding Dermata Therapeutics Warrant or generate 31.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	45.45%
Values	Daily Returns

BriaCell Therapeutics Corp  vs.  Dermata Therapeutics Warrant

BriaCell Therapeutics

Risk-Adjusted Performance

5 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in BriaCell Therapeutics Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, BriaCell Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Dermata Therapeutics

Risk-Adjusted Performance

13 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with BriaCell Therapeutics and Dermata Therapeutics

The main advantage of trading using opposite BriaCell Therapeutics and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if BriaCell Therapeutics position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.

The idea behind BriaCell Therapeutics Corp and Dermata Therapeutics Warrant pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.